DURHAM, N.C. – Eboo Pharmaceuticals Inc. (EPI) in Durham is one of three U.S. biopharmaceutical companies selected by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for its Partnering Program.
WINSTON-SALEM, N.C., March 17, 2014 /PRNewswire-USNewswire/ – Marcus Dobson first recognized the cognitive decline brought on by Parkinson’s disease when he realized he no longer wanted to play with his grandchildren or even be in the same room with them. Bunny Fontrier wasn’t having any cognition problems, but after caring for her mother with dementia she thought she should look at herself, too. Dobson, 60, and Fontrier, 63, are currently participating in a cognition-related exercise study at Wake Forest Baptist Medical Center in Winston-Salem, N.C.
Inhaling whole-plant cannabis provides symptomatic relief in patients with Parkinson’s disease (PD), according to observational trial data published in the March/April edition of the journal Clinical Neuropharmacology. Parkinson’s is a progressive disorder of the central nervous system that results in tremor, slowed movement, and muscle rigidity.
Investigators at Tel Aviv University, Department of Neurology evaluated Parkinson’s disease symptoms in 22 patients at baseline and 30-minutes after inhaling cannabis.
Researchers reported that inhaled cannabis was associated with “significant improvement after treatment in tremor, rigidity, and bradykinsea (slowness of movement). There was also significant improvement of sleep and pain scores. No significant adverse effects of the drug were observed.”
They concluded: “[T]his observational study is the first to report an amelioration of both motor and non–motor symptoms in patients with PD treated with cannabis. The study opens new venues for treatment strategies in PD especially in patients refractory to current medications.”
Israel has formally allowed for the licensed production and distribution of the substance for therapeutic purposes since 2011.
An abstract of the study, “Cannabis (Medical Marijuana) Treatment for Motor and Non–Motor Symptoms of Parkinson Disease: An Open-Label Observational Study,” is online here.
- See more at: http://blog.norml.org/2014/03/17/study-inhaled-cannabis-mitigates-parkinsons-disease-symptoms/#sthash.qUUxErsz.dpuf
REHOVOT, Israel–(BUSINESS WIRE)–Pharma Two B announced today that it is now enrolling patients for a Phase IIb study of its combination product, P2B001, for the treatment of the early stages of Parkinson’s disease (PD). Pharma Two B is following the FDA’s 505(b)(2) registration pathway for P2B001.
When you bring a piece of chocolate to your mouth, your brain responds by giving you a flood of dopamine, a chemical associated with pleasure — but that’s not dopamine’s only function. Local researchers think it may also play an important role in how the brain processes sound and communications.
Prions, the protein family notorious for causing “mad cow” and neurodegenerative diseases like Parkinson’s, can play an important role in healthy cells. “Do you think God created prions just to kill?” mused Nobel laureate Eric Kandel. “These things must have evolved initially to have a physiological function.” His work on memory helped reveal that animals make and use prions in their nervous systems as part of an essential function: stabilizing the synapses that constitute long-term memories.
(NaturalNews) Is it possible that the simple act of drinking green tea can help protect your brain against Parkinson’s and Alzheimer’s disease? A multitude of studies have looked into the effects that the tea has on neurological health — and the results are promising.
Ezose Sciences Inc. today announced that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research to apply Ezose’s GlycanMap® technology to investigating the role of the sugars known as glycans in Parkinson’s disease.
As medical researchers across disease states pursue better treatments, they all share one limiting factor. Estimates hold that 85 percent of all studies face delays and 30 percent never get off the ground due to a lack of clinical research volunteers. Slow patient enrollment diminishes the scientific power of studies, drives costs up and, most notably, delays improved therapies for patients.
A Dutch life science startup is collaborating with biotechnology companies to make it easier for patients with advanced chronic conditions and unable to get into clinical trials to access potentially life-saving drugs before they are cleared by regulators. MyTomorrows positions itself as a patient-focused company and recently raised $2.2 million from friends and family to expand the treatments available for this program to include amyotrophic lateral sclerosis or Lou Gehrig’s disease, multiple sclerosis and Parkinson’s disease, among others.